Mohamad Ali, A., Yassen, N. (2021). The Relationship of Urocortin 2 with Insulin Resistance, Clinical, and Biochemical Hyperandrogenism in Women with Polycystic Ovary Syndrome. , 21(2), 243-249. doi: 10.52573/ipmj.2021.174636
Alia Jasim Mohamad Ali; Najah Shaker Yassen. "The Relationship of Urocortin 2 with Insulin Resistance, Clinical, and Biochemical Hyperandrogenism in Women with Polycystic Ovary Syndrome". , 21, 2, 2021, 243-249. doi: 10.52573/ipmj.2021.174636
Mohamad Ali, A., Yassen, N. (2021). 'The Relationship of Urocortin 2 with Insulin Resistance, Clinical, and Biochemical Hyperandrogenism in Women with Polycystic Ovary Syndrome', , 21(2), pp. 243-249. doi: 10.52573/ipmj.2021.174636
Mohamad Ali, A., Yassen, N. The Relationship of Urocortin 2 with Insulin Resistance, Clinical, and Biochemical Hyperandrogenism in Women with Polycystic Ovary Syndrome. , 2021; 21(2): 243-249. doi: 10.52573/ipmj.2021.174636

The Relationship of Urocortin 2 with Insulin Resistance, Clinical, and Biochemical Hyperandrogenism in Women with Polycystic Ovary Syndrome

Iraqi Postgraduate Medical Journal
Article 17, Volume 21, Issue 2, 2022, Pages 243-249    PDF (313.71 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2021.174636
Authors
Alia Jasim Mohamad Ali1; Najah Shaker Yassen2
1Al-Alawia Teaching Hospital/Baghdad, Iraq
2Baghdad Teaching Hospital /Baghdad, Iraq
Abstract
BACKGROUND: 
Polycystic ovary syndrome is the most common endocrine and metabolic disorder in women. Urocotin-2 is thought to be involved in the pathophysiology of Polycystic ovary syndrome by paracrine and autocrine pathways.
OBJECTIVE:  
To assess the Urocortin-2 level in women with Polycystic ovary syndrome and to assess the relation of urocotin-2 with insulin resistance, clinical and biochemical hyperanderogenism.
PATIENTS AND METHOD: 
a case control study that involved; forty-five polycystic ovary patients according to Rotterdam criteria as a case group, and forty-five healthy women as a control group. Ferriman-Gallwey score was used to evaluate hirsutism, in addition to measurement of Body mass index and Waist/Hip ratio, levels of: Follicle stimulating hormone, luteinizing hormone, Prolactin, testosterone, insulin, fasting blood sugar, homeostatic model assessment of insulin resistance and urocotine-2 also assessed.      
RESULT:
urocotin-2 was significantly higher in Polycystic ovary syndrome compared to control women using Receiver Operating Characteristic Curve  analysis.
CONCLUSION:  
Urocortin-2 may have a role in the pathogenesis of Polycystic ovary syndrome for its correlation with testosterone, homeostatic model assessment of insulin resistance, serum insulin, and Body Mass Index, since there was higher levels than that of normal women.
Keywords
Polycystic ovary syndrome; urocortin-2; insulin resistance
References
  1.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England). 2004;19:41-47.
  2. Kashanian M, Fazy Z, Pirak A. Evaluation of the relationship between gestational diabetes and a history of polycystic ovarian syndrome. Diabetes Res Clin Pract. 2008;80:289-92.
  3. Maia LM, Rocha AL, Del Puerto HL, Petraglia F, Reis FM. Plasma urocortin-1 as a preoperative marker of endometriosis in symptomatic women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2018;34:202-5.
  4. Sossey-Alaoui K, Head K, Nowak N, Cowell JK. Genomic organization and expression profile of the human and mouse WAVE gene family. Mammalian genome : official journal of the International Mammalian Genome Society. 2003;14:314-22.
  5. Temur M, Yilmaz O, Aksun S, Calan M, Ozun Ozbay P, Kumbasar S, et al. The relationship of urocortin-2 with insulin resistance patients having PCOS. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2017;33:124-27.
  6. Li L, Zhang F, Cui J, Shi Y, Xiang J, Wang X, et al. Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2017;33:238-43.
  7. Temur M, Yilmaz O, Aksun S, Ozun Ozbay P, Calan M, Kume T, et al. Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2016;32:218-22.
  8. Ates S, Aydin S, Ozcan P, Soyman Z, Gokmen Karasu AF, Sevket O. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2018;38:236-40.
  9. Behboudi-Gandevani S, Ramezani Tehrani F, Cheraghi L, Azizi F. Could "a body shape index" and "waist to height ratio" predict insulin resistance and metabolic syndrome in polycystic ovary syndrome? European journal of obstetrics, gynecology, and reproductive biology. 2016;205:110-4.
10. Chen X, Ni R, Mo Y, Li L, Yang D. Appropriate BMI levels for PCOS patients in Southern China. Human reproduction (Oxford, England). 2010;25:1295-302

11. Ikeda K, Baba T, Noguchi H, Nagasawa K, Endo T, Kiya T, et al. Excessive androgen exposure in female-to-male transsexual persons of reproductive age induces hyperplasia of the ovarian cortex and stroma but not polycystic ovary morphology. Human reproduction (Oxford, England). 2013;28:453-61.

12. Spyroglou A, Riester A, Mueller-Peltzer K, Lu A, Rohde J, Hantel C, et al. Adrenal and Ovarian Phenotype of a Tissue-Specific Urocortin 2-Overexpressing Mouse Model. Endocrinology. 2015;156:2646-56.

 

Statistics
Article View: 270
PDF Download: 133


Journal Management System. Powered by iJournalPro.com